Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Liabilities (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Total Liabilities data on record, last reported at $153.7 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 7.82% year-over-year to $153.7 million; the TTM value through Dec 2025 reached $153.7 million, up 7.82%, while the annual FY2025 figure was $153.7 million, 7.82% up from the prior year.
  • Total Liabilities reached $153.7 million in Q4 2025 per OCUL's latest filing, up from $152.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $160.9 million in Q4 2023 and bottomed at $107.3 million in Q2 2022.
  • Average Total Liabilities over 5 years is $134.8 million, with a median of $138.9 million recorded in 2024.
  • The widest YoY moves for Total Liabilities: up 91.14% in 2021, down 37.08% in 2021.
  • A 5-year view of Total Liabilities shows it stood at $116.9 million in 2021, then dropped by 2.55% to $113.9 million in 2022, then skyrocketed by 41.28% to $160.9 million in 2023, then fell by 11.4% to $142.6 million in 2024, then rose by 7.82% to $153.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $153.7 million in Q4 2025, $152.7 million in Q3 2025, and $145.4 million in Q2 2025.